Kancera AB (publ)

As of June 30, 2025, Kancera AB (publ) has 121.19M shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 15,667.62, and the price-to-book ratio stands at -4.22.

These figures are as of June 30, 2025. The EV/Sales ratio of 13,696.33 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of June 30, 2025, Kancera AB (publ) maintains a current ratio of 8.02, meaning it holds 8.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2025. Return on assets (ROA) is negative at -56.04, reflecting losses generated across the asset base.

Over the twelve months ended June 30, 2025, Kancera AB (publ) posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -291,878.57 and net profit margin of -284,857.14 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Free cash flow yield is negative at -22.05: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

Kancera AB (publ)'s most recent stock split took place on February 29, 2024 with a 1000:1023 split ratio.

As of June 30, 2025, Kancera AB (publ) has an Altman Z-Score of 30.03, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.